Dendritic Cell Vaccines: Sipuleucel-T and Other Approaches

Nicholas M. Durham, Charles G. Drake

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The idea of a preventive vaccine against cancer has been extremely attractive because of the immune system's ability to develop specific and long-lasting immunological memory. Dendritic cells, which present antigen to T cells, sit at a critical point in the activation of the immune system because they are able to activate both B cells and T cells. The first DC vaccines were tested in humans in 1998. In 2010 the first DC vaccine was FDA approved for treatment of patients with advanced prostate cancer. This vaccine showed a survival advantage of 4.3 months. This vaccine was extremely safe, with low rates of adverse events. In this chapter we discuss the history of DC vaccines, the development of DC vaccines including Sipuleucel-T, and the future directions of DC vaccines. This includes strategies for combining DC vaccines with other therapies, including hormone therapy, additional immunotherapy, and chemotherapy.

Original languageEnglish (US)
Title of host publicationCancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition
PublisherElsevier Inc.
Pages273-286
Number of pages14
ISBN (Print)9780123942968
DOIs
StatePublished - Jul 2013

Keywords

  • Cancer
  • Dendritic cells
  • Hormone therapy
  • Immunotherapy
  • Lymphocyte
  • Sipuleucel-T
  • Vaccine

ASJC Scopus subject areas

  • Medicine(all)
  • Dentistry(all)

Fingerprint Dive into the research topics of 'Dendritic Cell Vaccines: Sipuleucel-T and Other Approaches'. Together they form a unique fingerprint.

Cite this